Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 7/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.46 |
| ▸ | SRC | P12931 | 8/20 | 0.44 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20059237 | 1.00 | ADK (0.47) | ADKPRMT5WDR77SRCDOT1L | |
| SCHEMBL20058772 | 0.89 | ADK (0.61) | ADKPRMT5SRCDOT1LNPC1 | |
| SCHEMBL15948739 | 0.89 | PRMT5 (0.47) | ADKPRMT5WDR77SRCDOT1L | |
| SCHEMBL10268710 | 0.89 | ADK (0.61) | ADKPRMT5SRCDOT1LNPC1 | |
| SCHEMBL14134801 | 0.88 | PRMT5 (0.48) | ADKPRMT5WDR77DOT1LNPC1 | |
| SCHEMBL22912603 | 0.88 | PRMT5 (0.48) | ADKPRMT5WDR77DOT1LNPC1 | |
| SCHEMBL14305600 | 0.87 | ADK (0.60) | ADK | |
| SCHEMBL14313964 | 0.87 | ADK (0.47) | ADKPRMT5SRCDOT1LNPC1 | |
| SCHEMBL14154378 | 0.87 | ADK (0.60) | ADKPRMT5WDR77RAB9A | |
| SCHEMBL14313959 | 0.85 | ADK (0.62) | ADKSRCDOT1LNPC1GALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902202-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090169504-A1 | Compounds and Pharmaceutical compositions for the treatment of Viral infections | IDENIX PHARMACEUTICALS, INC | 2009-07-02 | — | — | US | disclosed |
| US-20080280842-A1 | Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection | MERCK & CO., INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-7323453-B2 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK & CO., INC. (US) | 2008-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169504-A1 | Compounds and Pharmaceutical compositions for the treatment of Viral infections | HAVCR2, PYGL, GYS2 | ADK 1032/4885PRMT5 3572/4885WDR77 3471/4885 |
| US-20080280842-A1 | Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection | NSUN2, DUT, EFTUD2 | ADK 473/4885PRMT5 358/4885WDR77 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.